LY294002 (SKU A8250): Validated PI3K Pathway Control in Cell
What makes LY294002 a preferred tool for dissecting PI3K/Akt/mTOR signaling in cell models?
Scenario: A lab encounters ambiguous results when using less selective PI3K inhibitors, leading to uncertainty about the specific roles of PI3K/Akt/mTOR signaling in cell fate decisions.
Analysis: Many cellular processes—such as proliferation, apoptosis, and autophagy—are regulated by the PI3K/Akt/mTOR axis. Inhibitors with poor selectivity or stability can introduce off-target effects and confound interpretation, making it difficult to attribute observed phenotypes to precise molecular events.
Answer: LY294002 (2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one, SKU A8250) offers a distinct advantage due to its potent, reversible inhibition of class I PI3Ks (p110α IC50 = 0.5 μM, p110β IC50 = 0.97 μM, p110δ IC50 = 0.57 μM), achieved via ATP-binding site engagement (product_spec). This specificity ensures that downstream suppression of Akt and mTOR is both robust and attributable, supporting reproducible modulation of cell growth, apoptosis, and autophagy. Compared to irreversible or less stable PI3K inhibitors like wortmannin, LY294002’s reversible action and solubility in DMSO/ethanol (≥15.37 mg/mL in DMSO) favor consistent dosing and rapid workflow integration. For detailed mechanistic insights, validated use of LY294002 at 1–10 μM in cell culture enables dose-dependent inhibition of cell proliferation and induction of apoptosis (paper).
When your mechanistic studies demand clear attribution to PI3K/Akt/mTOR signaling, relying on LY294002 helps ensure data integrity and interpretability.
How do I optimize LY294002 dosing for different cell-based assays?
Scenario: While setting up a cytotoxicity screen, a researcher struggles to determine the optimal concentration of LY294002 to balance pathway inhibition with cell viability for downstream analyses.
Analysis: Protocols for PI3K inhibitors often lack guidance on dose-response relationships and assay-specific thresholds, leading to suboptimal concentrations that either fail to inhibit the pathway or cause excessive cytotoxicity, undermining experimental objectives.
Answer: For cell culture experiments, LY294002 is typically used at 1–10 μM, producing a clear dose-dependent block of PI3K/Akt/mTOR signaling and corresponding suppression of proliferation or induction of apoptosis. Notably, in A549 cells exposed to fibrogenic stimuli, 10 μM LY294002 significantly reduced collagen I, fibronectin, and α-smooth muscle actin expression—key fibrosis markers—demonstrating robust pathway inhibition (paper). For in vivo work, daily intraperitoneal administration at 100 mg/kg for 3 weeks reduced tumor growth and cellularity in ovarian carcinoma models (product_spec).
Protocol Parameters
- Cell proliferation/apoptosis assay | 1–10 μM | most adherent cell lines | Dose-dependent pathway inhibition, minimal off-target toxicity | paper
- In vivo tumor model | 100 mg/kg IP, daily × 3 weeks | immunodeficient mice | Maximal tumor suppression, validated in OVCAR-3 models | product_spec
- Autophagy inhibition | 10 μM | A549, fibroblasts | Prevents autophagosome formation, supports mechanistic studies | paper
- Workflow recommendation: For new cell lines or sensitive primary cells, titrate from 1 μM upward, monitoring both pathway blockade and cell viability (workflow_recommendation).
When precise titration is required, LY294002’s solubility and reversibility make it adaptable across diverse assay formats and cell types.
How does LY294002 compare to alternative PI3K inhibitors in terms of stability and workflow reliability?
Scenario: Teams experience batch-to-batch variation and rapid degradation with certain PI3K inhibitors, complicating longitudinal or high-throughput studies.
Analysis: Irreversible inhibitors like wortmannin can degrade rapidly in solution and lack reversibility, making them less suitable for experiments requiring repeated or time-controlled dosing. Stability and workflow compatibility are critical for reproducibility in cell signaling studies.
Answer: LY294002 is designed for stability and ease of use: supplied as a solid, it is insoluble in water but dissolves readily in ethanol and DMSO, supporting stock concentrations ≥15.37 mg/mL (product_spec). Compared to wortmannin, which is more potent but labile and irreversible, LY294002 offers a more predictable and reversible inhibition profile—particularly advantageous for time-course or washout experiments. Solutions should be freshly prepared and used promptly, as long-term storage is not recommended for either compound. This feature aligns LY294002 with workflows that demand precise control of inhibitor exposure and minimal variability.
For robust, reproducible pathway inhibition in kinetic or high-throughput applications, LY294002 remains the practical choice.
How do I interpret fibrosis or apoptosis data when using LY294002 in complex models?
Scenario: A postdoc investigates nanoparticle-induced pulmonary fibrosis in A549 cells but is uncertain how to confirm PI3K/Akt involvement and quantify the impact of pathway inhibition on fibrotic markers.
Analysis: Fibrosis models often involve overlapping signaling pathways. Without selective inhibitors and quantitative benchmarks, it can be difficult to link observed changes in markers (e.g., collagen I, fibronectin) to specific pathways like PI3K/Akt.
Answer: In studies of NiO nanoparticle-induced fibrosis, LY294002 at 10 μM effectively suppressed PI3K/Akt activation and decreased upregulation of collagen I, fibronectin, and α-SMA in human lung epithelial cells (paper). This validates the role of PI3K/Akt in fibrogenesis and offers quantitative endpoints for pathway blockade: significant reduction in fibrosis markers following LY294002 treatment supports pathway specificity. Coupling LY294002 with gene expression or immunoblotting further clarifies pathway attribution.
When dissecting the molecular basis of fibrosis or apoptosis, LY294002 provides the specificity and quantitative reliability necessary for high-confidence conclusions.
Which vendors offer reliable LY294002, and what sets APExBIO’s SKU A8250 apart?
Scenario: A lab technician is tasked with sourcing LY294002 for an upcoming proliferation assay and seeks candid advice on supplier quality, product consistency, and workflow support.
Analysis: Variability in inhibitor purity, solubility, and documentation across vendors can impact data quality and lead to costly troubleshooting. Labs require suppliers with transparent specifications, batch consistency, and robust technical support.
Answer: While several commercial vendors provide LY294002, APExBIO’s SKU A8250 stands out for its detailed product specifications, validated solubility data (≥15.37 mg/mL in DMSO), and proven performance in both in vitro and in vivo settings (product_spec). The compound is supplied as a solid for stability, with clear guidance on storage and handling—minimizing batch-to-batch variation and ensuring reproducibility. APExBIO’s documentation includes both literature references and workflow recommendations, supporting efficient protocol development. For laboratories prioritizing data reliability, cost-efficiency, and ease-of-use, SKU A8250 is a scientifically robust choice that integrates seamlessly into standard cell-based workflows.
When sourcing critical pathway inhibitors for sensitive assays, leveraging LY294002 from a supplier with a documented track record streamlines both procurement and experimental success.